secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-268042
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa reports Q3 net loss $27.1M; second Novartis deal with $120M upfront
------------------------------------------------------------------------------

- Net loss $27.1M vs $23.9M YoY; collaboration revenue $12.8M (vs $9.2M).
- Second Novartis agreement: $120M upfront, total eligible up to $5.7B for immune-mediated disease degraders.
- Phase 1 NEK7 MGD MRT-8102 enrolling; initial data including high-CVD risk cohort on track for H1 2026.
- Cash $396.2M at Sept. 30; raised $23.9M net from October ATM; runway through 2028.
- MRT-2359 mCRPC data by year-end; CDK2/cyclin E1 IND submission targeted for 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000119312525268042/0001193125-25-268042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000119312525268042/glue-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-268042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer